The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.
We performed a dose-escalation study of bendamustine in 31 patients with multiple myeloma that had progressed after high-dose chemotherapy. Bendamustine 100 mg/m2 on days 1 and 2 per cycle was found to be the maximal tolerated dose. The overall response rate was 55% with a median progression-free survival of 26 (0-61) weeks. Toxicity was mild and mainly hematologic.
Knop
Stefan
S
Straka
Christian
C
Haen
Michael
M
Schwedes
Renate
R
Hebart
Holger
H
Einsele
Hermann
H
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000069461:Bendamustine Hydrochloride; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000453:epidemiology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000453:epidemiology; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride